To keep you up-to-date on the latest scientific findings and on the clinical management of CML the iCMLf is pleased to present to you monthly updates from key CML publications in peer-reviewed journals.

The iCMLf 'Publications of the month' are brought to you by Professor Michele Baccarani this month. From the many papers on CML published this month Professor Baccarani has selected topical, interesting papers for your perusal including recent papers on CML and COVID-19.

Read Professor Baccarani's CML publications of the month: May 2021

Clinical papers

• Asciminib in chronic myeloid leukemia: Many questions still remain to be answered
  Eskazan AE. Blood Cancer J, April 2021 – open access publication
• Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib. ENESTop 5-year update
  Hughes TP et al. Leukemia, May 2021 (epub ahead of print)
• Why chronic myeloid leukemia cannot be cured by tyrosine kinase inhibitors
  Baccarani M and Gale RP. Leukemia, May 2021 (epub ahead of print)
• EUTOS long-term survival score discriminated different SOKAL score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study
  Breccia M et al. Leukemia, May 2021 (epub ahead of print)
• Budget impact of tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia with sustained deep molecular response
  Astruge C et al. Value Health, May 2021
• Relevance of treatment-free remission recommendations in chronic phase chronic myeloid leukemia patients treated with frontline tyrosine kinase inhibitors
  Etienne G et al. Cancer Med, May 2021 (epub ahead of print) – open access publication
• Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients
  Folta A et al. Leuk Lymphoma, May 2021
• Promyelocytic blast phase of chronic myeloid leukemia; BCR-ABL1 positive: Points to be considered at diagnosis
  Kim B et al. Ann Lab Med, May 2021 – open access publication
• Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: A real-world analysis of health plan enrolees
  Chow EJ et al. Leuk Lymphoma, May 2021
• An indirect comparison between bosutinib, nilotinib and dasatinib in chronic phase chronic myeloid leukemia
  Muresan B et al. Curr Med Res Opin, May 2021 (epub ahead of print)
• Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib
  Hall KH et al. Am J Hematol, May 2021 (epub ahead of print) – open access publication
• Current status and novel strategy for CML
  Morita K and Sasaki K. Int J Hematol, May 2021

Scientific papers

• Recent advances in understanding chronic myeloid leukemia: Where do we stand?
  Kumar R and Krause DS. Fac Rev, April 2021 – open access publication
• Validation of CIP2A as a biomarker of subsequent disease progression and treatment failure in chronic myeloid leukemia
  Clark RE et al. Cancers(Basel), May 2021 – open access publication
• Clonal evolution and clinical implications of genetic abnormalities in blastic transformation in chronic myeloid leukemia
  Ochi Y et al. Nat Commun, May 2021 – open access publication
• Sirtuin1 and chronic myeloid leukemia: A comprehensive glance of drug resistance
  Abbasian S et al. Clin Lab, May 2021
• Understanding the hematopoietic microenvironment in chronic myeloid leukemia: A concise review
  Torres-Barrera P et al. Curr Res Transl Med, May 2021 (epub ahead of print)
• Mutational landscape of chronic myeloid leukemia: more than a single oncogene
  Adnan-Awad S et al. Leuk Lymphoma, May 2021 (epub ahead of print)
• Suppression of USP1 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis
  Jiang S et al. Cell Death Dis, May 2021 – open access publication
• Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemic
  Lee H et al. Int J Hematol, May 2021

Pediatric papers

• Sudden blast phase in paediatric chronic myeloid leukemia-chronic phase with abnormal blasts detected by flow cytometry at diagnosis. Can it be considered a warning sign?
  Vijayasekharan K et al. Cytometry B Clin Cytom, May 2021

COVID-19 papers

COVID-19 and haematological malignancies

• COVID-19 vaccines for patients with haematological conditions
  Sun C et al. Lancet Hematol, May 2021 – open access publication

COVID-19 and cancer

• Mortality in hospitalized patients with cancer and coronavirus disease 2019: 
  A systematic review and meta-analysis of cohort studies
  Desai A et al. Cancer, May 2021 – open access publication